Citations (181)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (25)
Thamer A Almangour, Leen Ghonem, Ahmad Aljabri, Alya Alruwaili, Mohammed Al Musawa, Nader Damfu, Mesfer S Almalki, Majda Alattas, Hossam Abed, Doaa Naeem, Nawaf Almalki & Abdullah A Alhifany. (2022) Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study. Infection and Drug Resistance 15, pages 211-221.
Read now
Read now
M. C. Avilés Martínez, J. J. Alfaro Martínez, J. J. Blanch Sancho & J. Solís García del Pozo. (2022) Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trials. Journal of Chemotherapy 34:7, pages 419-426.
Read now
Read now
Emanuele Rando, Francesca Giovannenze, Rita Murri & Emilio Sacco. (2022) A review of recent advances in the treatment of adults with complicated urinary tract infection. Expert Review of Clinical Pharmacology 15:9, pages 1053-1066.
Read now
Read now
Mazen S. Bader, Mark Loeb, Daniela Leto & Annie A. Brooks. (2020) Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgraduate Medicine 132:3, pages 234-250.
Read now
Read now
Stan D Atkin, Shadaan Abid, Michael Foster, Moumita Bose, Ashley Keller, Rita Hollaway, Helio S Sader, David E Greenberg, James D Finklea, Mariana Castanheira & Raksha Jain. (2018) Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infection and Drug Resistance 11, pages 1499-1510.
Read now
Read now
Michael E. Plazak, Pranita D. Tamma & Emily L. Heil. (2018) The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria. Expert Opinion on Pharmacotherapy 19:18, pages 2019-2031.
Read now
Read now
Matteo Bassetti, Alessandro Russo, Alessia Carnelutti, Alessandro La Rosa & Elda Righi. (2018) Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opinion on Drug Safety 17:7, pages 669-680.
Read now
Read now
Marco Falcone, Pierluigi Viale, Giusy Tiseo & Manjunath Pai. (2018) Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Expert Opinion on Drug Metabolism & Toxicology 14:3, pages 331-340.
Read now
Read now
Mengmeng Chen, Minjie Zhang, Peixian Huang, Qiongyu Lin, Cheng Sun, Hongke Zeng & Yiyu Deng. (2018) Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials. Expert Review of Anti-infective Therapy 16:2, pages 111-120.
Read now
Read now
Katherine L. Roberts, Scott T. Micek, Paul Juang & Marin H. Kollef. (2017) Controversies and advances in the management of ventilator associated pneumonia. Expert Review of Respiratory Medicine 11:11, pages 875-884.
Read now
Read now
Joshua T. Thaden, Jason M. Pogue & Keith S. Kaye. (2017) Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 8:4, pages 403-416.
Read now
Read now
Mazen S Bader, Mark Loeb & Annie A Brooks. (2017) An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate Medicine 129:2, pages 242-258.
Read now
Read now
Aneela Majeed, Sumaiah Alarfaj, Rabih Darouiche & Mayar Mohajer. (2017) An update on emerging therapies for urinary tract infections. Expert Opinion on Emerging Drugs 22:1, pages 53-62.
Read now
Read now
Jose A Hidalgo, Celeste M Vinluan & Nishaal Antony. (2016) Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Drug Design, Development and Therapy 10, pages 2379-2386.
Read now
Read now
Ivan Gentile, Alberto Enrico Maraolo & Guglielmo Borgia. (2016) What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?. Expert Review of Anti-infective Therapy 14:10, pages 875-878.
Read now
Read now
Vicenç Falcó, Joaquin Burgos, Elisabeth Papiol, Ricard Ferrer & Benito Almirante. (2016) Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. Expert Opinion on Investigational Drugs 25:6, pages 653-665.
Read now
Read now
Bradley J. Gardiner & Yoav Golan. (2016) Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. Expert Review of Anti-infective Therapy 14:5, pages 451-463.
Read now
Read now
Federico Perez, Nadim G. El Chakhtoura, Krisztina M. Papp-Wallace, Brigid M. Wilson & Robert A. Bonomo. (2016) Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?. Expert Opinion on Pharmacotherapy 17:6, pages 761-781.
Read now
Read now
Sergio Ramírez-Estrada, Bárbara Borgatta & Jordi Rello. (2016) Pseudomonas aeruginosa ventilator-associated pneumonia management. Infection and Drug Resistance 9, pages 7-18.
Read now
Read now
Yogesh Mawal, Ian A Critchley, Todd A Riccobene & Angela K Talley. (2015) Ceftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Review of Clinical Pharmacology 8:6, pages 691-707.
Read now
Read now
David P Nicolau. (2015) Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opinion on Investigational Drugs 24:9, pages 1261-1273.
Read now
Read now
Abrar K Thabit, Jared L Crandon & David P Nicolau. (2015) Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opinion on Pharmacotherapy 16:2, pages 159-177.
Read now
Read now
Philippe Lagacé-Wiens, Andrew Walkty & James A Karlowsky. (2014) Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infectionsinfections. Core Evidence 9, pages 13-25.
Read now
Read now
Robert K. Flamm, Gregory G. Stone, Helio S. Sader, Ronald N. Jones & Wright W. Nichols. (2014) Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. Journal of Chemotherapy 26:6, pages 333-338.
Read now
Read now
Ilias Karaiskos & Helen Giamarellou. (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy 15:10, pages 1351-1370.
Read now
Read now
Articles from other publishers (156)
Meng-Hsuan Lin, Yi-Cheng Shen, Han-Yun Cheng, Chi-Kang Teng, Wei-Cheng Chen, Yu-Chao Lin & Chin-Chuan Hung. (2023) Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials. Journal of Global Antimicrobial Resistance 34, pages 46-58.
Crossref
Crossref
François Barbier, Sami Hraiech, Solen Kernéis, Nathanaël Veluppillai, Olivier Pajot, Julien Poissy, Damien Roux & Jean-Ralph Zahar. (2023) Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Annals of Intensive Care 13:1.
Crossref
Crossref
Kuo-Chuan Hung, Wen-Wen Tsai, Chin-Wei Hsu, Chih-Cheng Lai, Hung-Jen Tang & I-Wen Chen. (2023) Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials. International Journal of Antimicrobial Agents 62:1, pages 106830.
Crossref
Crossref
Wright W Nichols, Patricia A Bradford & Gregory G Stone. (2023) The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment. Journal of Antimicrobial Chemotherapy 78:4, pages 871-892.
Crossref
Crossref
Lauren Hetzler, Marin H. Kollef, Valerie Yuenger, Scott T. Micek & Kevin D. Betthauser. (2022) New antimicrobial treatment options for severe Gram-negative infections. Current Opinion in Critical Care 28:5, pages 522-533.
Crossref
Crossref
Wright W Nichols, Patricia A Bradford & Gregory G Stone. (2022)
The primary pharmacology of ceftazidime/avibactam:
in vivo
translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
. Journal of Antimicrobial Chemotherapy 77:9, pages 2341-2352.
Crossref
Crossref
Sunil Kumar, Razique Anwer, Mukesh Yadav, Gourav Vats, Shivali Thakur, Nirmala Sehrawat, Vikas Kumar & Manoj Singh. (2022) An Update on Advancements in Treatment Options for Managing Klebsiella pneumoniae Infections. Current Pharmacology Reports 8:6, pages 439-449.
Crossref
Crossref
Yukiko Ezure, Veronica Rico, David L Paterson, Lisa Hall, Patrick N A Harris, Alex Soriano, Jason A Roberts, Matteo Bassetti, Matthew J Roberts, Elda Righi & Hugh Wright. (2022) Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases 9:5.
Crossref
Crossref
Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli & Jesús Rodríguez-Baño. (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection 28:4, pages 521-547.
Crossref
Crossref
Xianhai Huang & David Yu‐Kai Chen. 2022. Contemporary Accounts in Drug Discovery and Development. Contemporary Accounts in Drug Discovery and Development
341
384
.
Andrew Chou, Elwyn Welch, Andrew Hunter & Barbara W. Trautner. (2022) Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review. Drugs 82:4, pages 407-438.
Crossref
Crossref
Frank Jones, Yanmin Hu & Anthony Coates. (2022) The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings. Antibiotics 11:3, pages 323.
Crossref
Crossref
Ryan Dillon, Jennifer Uyei, Rajpal Singh & Eilish McCann. (2021) Antibacterial data synthesis challenges: a systematic review of treatments for complicated Gram-negative urinary tract infections. Journal of Comparative Effectiveness Research 10:18, pages 1385-1400.
Crossref
Crossref
Matteo Bassetti, Daniele Roberto Giacobbe, Nadia Castaldo, Alessandro Russo & Antonio Vena. (2021) Role of new antibiotics in extended-spectrum β-lactamase-, AmpC- infections. Current Opinion in Infectious Diseases 34:6, pages 748-755.
Crossref
Crossref
James Harrison, John A. Weaver, Maya Desai & Jonathan A.G. Cox. (2021) In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex. The Cell Surface 7, pages 100064.
Crossref
Crossref
Alex Soriano, Yehuda Carmeli, Ali S. Omrani, Luke S. P. Moore, Margaret Tawadrous & Paurus Irani. (2021) Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infectious Diseases and Therapy 10:4, pages 1989-2034.
Crossref
Crossref
John E. Mazuski, Florian Wagenlehner, Antoni Torres, Yehuda Carmeli, Joseph W. Chow, Dalia Wajsbrot, Gregory G. Stone, Paurus Irani, David Bharucha, Karen Cheng & Margaret Tawadrous. (2021) Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infectious Diseases and Therapy 10:4, pages 2399-2414.
Crossref
Crossref
Mario Tumbarello, Francesca Raffaelli, Maddalena Giannella, Elisabetta Mantengoli, Alessandra Mularoni, Mario Venditti, Francesco Giuseppe De Rosa, Loredana Sarmati, Matteo Bassetti, Gaetano Brindicci, Marianna Rossi, Roberto Luzzati, Paolo Antonio Grossi, Alberto Corona, Alessandro Capone, Marco Falcone, Cristina Mussini, Enrico Maria Trecarichi, Antonio Cascio, Elena Guffanti, Alessandro Russo, Gennaro De Pascale, Carlo Tascini, Ivan Gentile, Angela Raffaella Losito, Linda Bussini, Giampaolo Corti, Giancarlo Ceccarelli, Silvia Corcione, Mirko Compagno, Daniele Roberto Giacobbe, Annalisa Saracino, Massimo Fantoni, Spinello Antinori, Maddalena Peghin, Paolo Bonfanti, Alessandra Oliva, Andrea De Gasperi, Giusy Tiseo, Cristina Rovelli, Marianna Meschiari, Nour Shbaklo, Teresa Spanu, Roberto Cauda & Pierluigi Viale. (2021)
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing
K. pneumoniae
Infections: A Retrospective Observational Multicenter Study
. Clinical Infectious Diseases 73:9, pages 1664-1676.
Crossref
Crossref
Søren Brøgger Christensen. (2021) Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β-Lactams. Molecules 26:19, pages 6057.
Crossref
Crossref
Huan Zhang, Beibei Liang, Jin Wang & Yun Cai. (2021) Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review. International Journal of Antimicrobial Agents 58:4, pages 106410.
Crossref
Crossref
Etedad Nour Alla Eadl Elbasier Suliman, Dixon Thomas, Asim Ahmed Elnour, Nimmy Robin & Mark Maas. (2021) Systematic review on the choice of antibiotics for management of complicated urinary tract bacterial infections and acute pyelonephritis. Drugs & Therapy Perspectives 37:10, pages 470-479.
Crossref
Crossref
George L. Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G. Stone, Nathalie Baillon-Plot, Margaret Tawadrous & Paurus Irani. (2021) Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. Antibiotics 10:9, pages 1126.
Crossref
Crossref
Ruiying Han, Mengmeng Teng, Ying Zhang, Tao Zhang, Taotao Wang, Jiaojiao Chen, Sihan Li, Bo Yang, Yaling Shi, Yalin Dong & Yan Wang. (2021) Choosing Optimal Antibiotics for the Treatment of Patients Infected With Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Dafna Yahav, Noam Tau & Daniel Shepshelovich. (2021) Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria. Clinical Infectious Diseases 72:11, pages 1968-1974.
Crossref
Crossref
Michael J Satlin. (2021) Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins. Clinical Infectious Diseases 72:4, pages 622-625.
Crossref
Crossref
Geneva M. Wilson, Margaret A. Fitzpatrick, Kyle Walding, Beverly Gonzalez, Marin L. Schweizer, Katie J. Suda & Charlesnika T. Evans. (2021) Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis. Antimicrobial Stewardship & Healthcare Epidemiology 1:1.
Crossref
Crossref
Dafna Yahav, Christian G. Giske, Alise Grāmatniece, Henrietta Abodakpi, Vincent H. Tam & Leonard Leibovici. (2020) New β-Lactam–β-Lactamase Inhibitor Combinations. Clinical Microbiology Reviews 34:1.
Crossref
Crossref
Burcu Isler, Yukiko Ezure, Jose Luis García-Fogeda Romero, Patrick Harris, Adam G. Stewart & David L. Paterson. (2020)
Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
Enterobacterales
?: a Systematic Review and Meta-analysis
. Antimicrobial Agents and Chemotherapy 65:1.
Crossref
Crossref
T. ten Doesschate, T.W. van der Vaart, J.A.A. Damen, M.J.M. Bonten & C.H. van Werkhoven. (2020) Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials. Journal of Infection 81:4, pages 499-509.
Crossref
Crossref
Jameela Al Salman, Laila Al Dabal, Matteo Bassetti, Wadha A. Alfouzan, Muna Al Maslamani, Basem Alraddadi, Ashraf Elhoufi, Mushira Enani, Faryal Ali Khamis, Eiman Mokkadas, Ingy Romany, Ali Somily & Souha Kanj. (2020) Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. International Journal of Antimicrobial Agents 56:4, pages 106104.
Crossref
Crossref
Karen Cheng, Paul Newell, Joseph W. Chow, Helen Broadhurst, David Wilson, Katrina Yates & Angela Wardman. (2020) Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Safety 43:8, pages 751-766.
Crossref
Crossref
Marco Fiore, Aniello Alfieri, Sveva Di Franco, Maria Caterina Pace, Vittorio Simeon, Giulia Ingoglia & Andrea Cortegiani. (2020) Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics 9:7, pages 388.
Crossref
Crossref
Beatriz Dietl, Laura M Martínez, Esther Calbo & Javier Garau. (2020) Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiology 15:7, pages 473-484.
Crossref
Crossref
Li-Chin Lu, Chih-Cheng Lai, Shen-Peng Chang, Shao-Huan Lan, Shun-Hsing Hung & Wei-Ting Lin. (2020) Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections. Medicine 99:19, pages e19960.
Crossref
Crossref
Gregory G. Stone, Patricia A. Bradford, Margaret Tawadrous, Dianna Taylor, Mary Jane Cadatal, Zhangjing Chen & Joseph W. Chow. (2020)
In Vitro
Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
. Antimicrobial Agents and Chemotherapy 64:5.
Crossref
Crossref
Jianguo Li, Mark Lovern, Todd Riccobene, Timothy J. Carrothers, Paul Newell, Shampa Das, Angela K. Talley & Margaret Tawadrous. (2020) Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy 64:4.
Crossref
Crossref
Shampa Das, Diansong Zhou, Wright W. Nichols, Andy Townsend, Paul Newell & Jianguo Li. (2019) Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology 76:3, pages 349-361.
Crossref
Crossref
Alessandro Russo. (2020) Spotlight on New Antibiotics for the Treatment of Pneumonia. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 14, pages 117954842098278.
Crossref
Crossref
Xinmei Tan, Qiwen Pan, Changgan Mo, Xianshu Li, Xueyan Liang, Yan Li, Yingnian Lan & Lingyuan Chen. (2020) Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection. Medicine 99:2, pages e18769.
Crossref
Crossref
Ashutosh Gupta & Abhay K. Pandey. 2020. Phytochemicals as Lead Compounds for New Drug Discovery. Phytochemicals as Lead Compounds for New Drug Discovery
275
292
.
Matteo Bassetti & Elda Righi. 2020. Approaching Complex Diseases. Approaching Complex Diseases
457
480
.
Che-Kim Tan, Chih-Cheng Lai & Chien-Ming Chao. (2019) Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections. Antibiotics 8:4, pages 255.
Crossref
Crossref
Haoyue Che, Rui Wang, Jin Wang & Yun Cai. (2019) Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 54:6, pages 809-813.
Crossref
Crossref
Chi Phuong Nguyen, Thuc Nguyen Dan Do, Roger Bruggemann, Jaap ten Oever, Eva Kolwijck, Eddy M.M. Adang & Heiman F.L. Wertheim. (2019) Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. International Journal of Antimicrobial Agents 54:6, pages 790-797.
Crossref
Crossref
Simone Lanini, John P A Ioannidis, Francesco Vairo, Michel Pletschette, Gina Portella, Virginia Di Bari, Alessia Mammone, Raffaella Pisapia, Stefano Merler, Boniface Nguhuni, Martin Langer, Antonino Di Caro, Sarah J L Edwards, Nicola Petrosillo, Alimuddin Zumla & Giuseppe Ippolito. (2019) Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. The Lancet Infectious Diseases 19:12, pages e444-e451.
Crossref
Crossref
Paige Soukup, Andrew C. Faust, Vindhya Edpuganti, William C. Putnam & James A. McKinnell. (2019)
Steady‐State Ceftazidime‐Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for
Pseudomonas aeruginosa
Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39:12, pages 1216-1222.
Crossref
Crossref
Thitima Kongnakorn, Florian Wagenlehner, Marco Falcone, Eszter Tichy, Roberto Di Virgilio, Nathalie Baillon-Plot & Claudie Charbonneau. (2019) Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. International Journal of Antimicrobial Agents 54:5, pages 633-641.
Crossref
Crossref
D. C. Richter, T. Brenner, A. Brinkmann, B. Grabein, M. Hochreiter, A. Heininger, D. Störzinger, J. Briegel, M. Pletz, M. A. Weigand & C. Lichtenstern. (2019) Neue Antibiotika bei schweren Infektionen durch multiresistente ErregerNew antibiotics for severe infections due to multidrug-resistant pathogens. Der Anaesthesist 68:11, pages 785-800.
Crossref
Crossref
Stephanie M. Pouch & Gopi Patel. (2019) Multidrug‐resistant Gram‐negative bacterial infections in solid organ transplant recipients—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 33:9.
Crossref
Crossref
John S. Bradley, Emmanuel Roilides, Helen Broadhurst, Karen Cheng, Li-Min Huang, Veronica MasCasullo, Paul Newell, Gregory G. Stone, Margaret Tawadrous, Dalia Wajsbrot, Katrina Yates & Annie Gardner. (2019) Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. Pediatric Infectious Disease Journal 38:9, pages 920-928.
Crossref
Crossref
Xiaokui Huo, Qiang Meng, Changyuan Wang, Yanna Zhu, Zhihao Liu, Xiaodong Ma, Xiaochi Ma, Jinyong Peng, Huijun Sun & Kexin Liu. (2019) Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs). Acta Pharmaceutica Sinica B 9:5, pages 986-996.
Crossref
Crossref
Pranita D Tamma & Alice J Hsu. (2019) Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms. Journal of the Pediatric Infectious Diseases Society 8:3, pages 251-260.
Crossref
Crossref
Sherwin K. B. Sy, Luning Zhuang, Serubbabel Sy & Hartmut Derendorf. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clinical Pharmacokinetics 58:5, pages 545-564.
Crossref
Crossref
A. Hecker, M. Reichert, C. J. Reuß, T. Schmoch, J. G. Riedel, E. Schneck, W. Padberg, M. A. Weigand & M. Hecker. (2019) Intra-abdominal sepsis: new definitions and current clinical standards. Langenbeck's Archives of Surgery 404:3, pages 257-271.
Crossref
Crossref
Shampa Das, Jianguo Li, Todd Riccobene, Timothy J. Carrothers, Paul Newell, David Melnick, Ian A. Critchley, Gregory G. Stone & Wright W. Nichols. (2019) Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy 63:4.
Crossref
Crossref
Cristina De la Calle, Olga Rodríguez, Laura Morata, Francesc Marco, Celia Cardozo, Carolina García-Vidal, Ana Del Río, Csaba Feher, Martina Pellicé, Pedro Puerta-Alcalde, Josep Mensa, Alex Soriano & Jose Antonio Martínez. (2019) Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. International Journal of Antimicrobial Agents 53:4, pages 520-524.
Crossref
Crossref
Jianguo Li, Mark Lovern, Michelle L. Green, Joannellyn Chiu, Diansong Zhou, Craig Comisar, Yuan Xiong, Jeremy Hing, Merran MacPherson, James G. Wright, Todd Riccobene, Timothy J. Carrothers & Shampa Das. (2018) Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clinical and Translational Science 12:2, pages 151-163.
Crossref
Crossref
Mario Tumbarello, Enrico Maria Trecarichi, Alberto Corona, Francesco Giuseppe De Rosa, Matteo Bassetti, Cristina Mussini, Francesco Menichetti, Claudio Viscoli, Caterina Campoli, Mario Venditti, Andrea De Gasperi, Alessandra Mularoni, Carlo Tascini, Giustino Parruti, Carlo Pallotto, Simona Sica, Ercole Concia, Rosario Cultrera, Gennaro De Pascale, Alessandro Capone, Spinello Antinori, Silvia Corcione, Elda Righi, Angela Raffaella Losito, Margherita Digaetano, Francesco Amadori, Daniele Roberto Giacobbe, Giancarlo Ceccarelli, Ernestina Mazza, Francesca Raffaelli, Teresa Spanu, Roberto Cauda & Pierluigi Viale. (2019)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by
Klebsiella pneumoniae
Carbapenemase–producing
K. pneumoniae
. Clinical Infectious Diseases 68:3, pages 355-364.
Crossref
Crossref
M. Bassetti, E. Righi & A. Carnelutti. 2019. Annual Update in Intensive Care and Emergency Medicine 2019. Annual Update in Intensive Care and Emergency Medicine 2019
477
495
.
Olga Rodríguez-Núñez, Marco Ripa, Laura Morata, Cristina de la Calle, Celia Cardozo, Csaba Fehér, Martina Pellicé, Andrea Valcárcel, Pedro Puerta-Alcalde, Francesc Marco, Carolina García-Vidal, Ana del Río, Alex Soriano & Jose Antonio Martínez-Martínez. (2018) Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Journal of Global Antimicrobial Resistance 15, pages 136-139.
Crossref
Crossref
Matteo Bassetti, Elda Righi, Alessandro Russo & Alessia Carnelutti. (2018) New Antibiotics for Pneumonia. Clinics in Chest Medicine 39:4, pages 853-869.
Crossref
Crossref
Simon Portsmouth, David van Veenhuyzen, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu, Peter Tenke & Tsutae Den Nagata. (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases 18:12, pages 1319-1328.
Crossref
Crossref
Han Zhong, Xian-Yuan Zhao, Zai-Li Zhang, Zhi-Chun Gu, Chi Zhang, Yuan Gao & Min Cui. (2018) Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 52:4, pages 443-450.
Crossref
Crossref
A. Van Dalem, M. Herpol, F. Echahidi, C. Peeters, I. Wybo, E. De Wachter, P. Vandamme & D. Piérard. (2018)
In Vitro
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam
. Antimicrobial Agents and Chemotherapy 62:9.
Crossref
Crossref
Neta Sternbach, Yaara Leibovici Weissman, Tomer Avni & Dafna Yahav. (2018) Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 73:8, pages 2021-2029.
Crossref
Crossref
Lynn Nguyen, Joshua Garcia, Katherine Gruenberg & Conan MacDougall. (2018) Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?. Current Infectious Disease Reports 20:8.
Crossref
Crossref
Cecilia Pozzi, Flavio Di Pisa, Filomena De Luca, Manuela Benvenuti, Jean Denis Docquier & Stefano Mangani. (2018) Atomic-Resolution Structure of a Class C β-Lactamase and Its Complex with Avibactam. ChemMedChem 13:14, pages 1437-1446.
Crossref
Crossref
Nashaat S. Hamza & Abdalla Khalil. 2018. Urinary Tract Infection - The Result of the Strength of the Pathogen, or the Weakness of the Host. Urinary Tract Infection - The Result of the Strength of the Pathogen, or the Weakness of the Host.
Barbara A. Santevecchi, Tiffeny T. Smith & Shawn H. MacVane. (2018) Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. International Journal of Antimicrobial Agents 51:4, pages 629-635.
Crossref
Crossref
Felipe Francisco Tuon, Jaime L. Rocha & Marcelo R. Formigoni-Pinto. (2017) Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review. Infection 46:2, pages 165-181.
Crossref
Crossref
Yue Zhang, Li-na Tao, Xiao-yu Qu, Jun-qi Niu, Yan-hua Ding & Si-xi Zhang. (2018) Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials. Revista da Associação Médica Brasileira 64:3, pages 253-263.
Crossref
Crossref
Peter M Hawkey, Roderic E Warren, David M Livermore, Cliodna A M McNulty, David A Enoch, Jonathan A Otter & A Peter R Wilson. (2018) Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy 73:suppl_3, pages iii2-iii78.
Crossref
Crossref
Antoni Torres, Nanshan Zhong, Jan Pachl, Jean-François Timsit, Marin Kollef, Zhangjing Chen, Jie Song, Dianna Taylor, Peter J Laud, Gregory G Stone & Joseph W Chow. (2018) Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. The Lancet Infectious Diseases 18:3, pages 285-295.
Crossref
Crossref
Roman S. Kozlov, Olga U. Stetsiouk & Irina V. Andreeva. (2018) Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria. Clinical Microbiology and Antimicrobial Chemotherapy 20:1, pages 24-34.
Crossref
Crossref
Kamaleddin H. M. E. Tehrani & Nathaniel I. Martin. (2018) β-lactam/β-lactamase inhibitor combinations: an update. MedChemComm 9:9, pages 1439-1456.
Crossref
Crossref
Andreas Hecker, Birgit Hecker, Christoph Lichtenstern, Matthias Hecker, Jens G. Riedel, Markus A. Weigand & Winfried Padberg. 2018. Abdominal Sepsis. Abdominal Sepsis
211
224
.
Jakhongir F Alidjanov, Moritz Fritzenwanker, Ivan Hoffman & Florian M Wagenlehner. (2017) Ceftazidime–avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. Future Microbiology 12:8, pages 655-670.
Crossref
Crossref
Fiorella Krapp, Jennifer L. Grant, Sarah H. Sutton, Egon A. Ozer & Viktorija O. Barr. (2017) Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. International Journal of Antimicrobial Agents 49:6, pages 770-773.
Crossref
Crossref
Xinyu Qin, Binh Giang Tran, Min Ja Kim, Lie Wang, Dung Anh Nguyen, Qian Chen, Jie Song, Peter J. Laud, Gregory G. Stone & Joseph W. Chow. (2017) A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. International Journal of Antimicrobial Agents 49:5, pages 579-588.
Crossref
Crossref
Darren Wong & David van Duin. (2017) Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. Drugs 77:6, pages 615-628.
Crossref
Crossref
J. Rademacher & T. Welte. (2017) Neue Antibiotika – Stillstand oder FortschrittNew antibiotics – standstill or progress. Medizinische Klinik - Intensivmedizin und Notfallmedizin 112:3, pages 206-213.
Crossref
Crossref
C.-E. Lemaoui, H. Layaida, A. Badi & N. Foudi. (2017) Stratégies actuelles de lutte contre la résistance aux antibiotiques. Journal des Anti-infectieux 19:1, pages 12-19.
Crossref
Crossref
Elizabeth Temkin, Julian Torre-Cisneros, Bojana Beovic, Natividad Benito, Maddalena Giannella, Raúl Gilarranz, Cameron Jeremiah, Belén Loeches, Isabel Machuca, María José Jiménez-Martín, José Antonio Martínez, Marta Mora-Rillo, Enrique Navas, Michael Osthoff, Juan Carlos Pozo, Juan Carlos Ramos Ramos, Marina Rodriguez, Miguel Sánchez-García, Pierluigi Viale, Michel Wolff & Yehuda Carmeli. (2017) Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrobial Agents and Chemotherapy 61:2.
Crossref
Crossref
Henri Merdjan, Antoine Tarral, Shampa Das & Jianguo Li. (2017) Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. The Journal of Clinical Pharmacology 57:2, pages 211-218.
Crossref
Crossref
Shawn H. MacVane. (2016) Antimicrobial Resistance in the Intensive Care Unit. Journal of Intensive Care Medicine 32:1, pages 25-37.
Crossref
Crossref
Lindsay E. Nicolle. 2017. Infectious Diseases. Infectious Diseases
539
546.e1
.
Chien-Ming Chao, Chi-Chung Chen, Hui-Ling Huang, Yin-Ching Chuang, Chih-Cheng Lai & Hung-Jen Tang. (2016) Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections. PLOS ONE 11:12, pages e0167522.
Crossref
Crossref
Jean-Louis Vincent, Matteo Bassetti, Bruno François, George Karam, Jean Chastre, Antoni Torres, Jason A. Roberts, Fabio S. Taccone, Jordi Rello, Thierry Calandra, Daniel De Backer, Tobias Welte & Massimo Antonelli. (2016) Advances in antibiotic therapy in the critically ill. Critical Care 20:1.
Crossref
Crossref
Dana R. Bowers & Vanthida Huang. (2016) Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE). Current Infectious Disease Reports 18:12.
Crossref
Crossref
John J. Veillette, James Truong & Steven C. Forland. (2016)
Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing
Klebsiella pneumoniae
Bacteremia and Renal Impairment
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:11, pages e172-e177.
Crossref
Crossref
John S. Bradley, Jon Armstrong, Antonio Arrieta, Raafat Bishai, Shampa Das, Shirley Delair, Timi Edeki, William C. Holmes, Jianguo Li, Kathryn S. Moffett, Deepa Mukundan, Norma Perez, José R. Romero, David Speicher, Janice E. Sullivan & Diansong Zhou. (2016) Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Antimicrobial Agents and Chemotherapy 60:10, pages 6252-6259.
Crossref
Crossref
Marco Falcone & David Paterson. (2016) Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy 71:10, pages 2713-2722.
Crossref
Crossref
Florian M. Wagenlehner, Jack D. Sobel, Paul Newell, Jon Armstrong, Xiangning Huang, Gregory G. Stone, Katrina Yates & Leanne B. Gasink. (2016) Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clinical Infectious Diseases 63:6, pages 754-762.
Crossref
Crossref
David van Duin & Robert A. Bonomo. (2016) Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clinical Infectious Diseases 63:2, pages 234-241.
Crossref
Crossref
Elizabeth CerceoSteven B. DeitelzweigBradley M. ShermanAlpesh N. Amin. (2016) Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance 22:5, pages 412-431.
Crossref
Crossref
Andrew W. Hahn, Rupali Jain & David H. Spach. (2016) New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents. Medical Clinics of North America 100:4, pages 911-926.
Crossref
Crossref
David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem & Christopher J Schofield. (2016) The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam. Future Medicinal Chemistry 8:10, pages 1063-1084.
Crossref
Crossref
John E. Mazuski, Leanne B. Gasink, Jon Armstrong, Helen Broadhurst, Greg G. Stone, Douglas Rank, Lily Llorens, Paul Newell & Jan Pachl. (2016) Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clinical Infectious Diseases 62:11, pages 1380-1389.
Crossref
Crossref
Yehuda Carmeli, Jon Armstrong, Peter J Laud, Paul Newell, Greg Stone, Angela Wardman & Leanne B Gasink. (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. The Lancet Infectious Diseases 16:6, pages 661-673.
Crossref
Crossref
Navaneeth Narayanan, Linda Johnson & Conan MacDougall. (2016) Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases. The Journal of Pediatric Pharmacology and Therapeutics 21:2, pages 110-119.
Crossref
Crossref
Rodrigo E. Mendes, Mariana Castanheira, Leanne Gasink, Gregory G. Stone, Wright W. Nichols, Robert K. Flamm & Ronald N. Jones. (2016) β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrobial Agents and Chemotherapy 60:3, pages 1328-1335.
Crossref
Crossref
Roopali Sharma, Tae Eun Park & Stanley Moy. (2016) Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Clinical Therapeutics 38:3, pages 431-444.
Crossref
Crossref
Patrick N. A. Harris, Jane Y. Wei, Andrew W. Shen, Ahmed A. Abdile, Stuart Paynter, Rachel R. Huxley, Nirmala Pandeya, Yohei Doi, Kyungmin Huh, Catherine S. O'Neal, Thomas R. Talbot & David L. Paterson. (2016)
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by
Enterobacter
,
Citrobacter
or
Serratia
species: a systematic review with meta-analysis
. Journal of Antimicrobial Chemotherapy 71:2, pages 296-306.
Crossref
Crossref
Jianguo Li, Maria Learoyd, Furong Qiu, LeiLei Zhu & Timi Edeki. (2015) A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Clinical Drug Investigation 36:2, pages 119-126.
Crossref
Crossref
Hwanho Choi, Robert S. Paton, Hwangseo Park & Christopher J. Schofield. (2016) Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition. Organic & Biomolecular Chemistry 14:17, pages 4116-4128.
Crossref
Crossref
Kathleen Chiotos, Jennifer H. Han & Pranita D. Tamma. (2015) Carbapenem-Resistant Enterobacteriaceae Infections in Children. Current Infectious Disease Reports 18:1.
Crossref
Crossref
Olga M. Klibanov, Diep Phan & Kelli Ferguson. (2015) Drug updates and approvals. The Nurse Practitioner 40:12, pages 34-43.
Crossref
Crossref
Sarah Tennant, Donna Burgess, Jeffrey Rybak, Craig Martin & David Burgess. (2015) Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy. Antibiotics 4:4, pages 643-652.
Crossref
Crossref
Yoav Golan. (2015) Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infectious Diseases 15:1.
Crossref
Crossref
Matteo Bassetti, Davide Pecori, Marcella Sibani, Silvia Corcione & Francesco Giuseppe De Rosa. (2015) Epidemiology and Treatment of MDR Enterobacteriaceae. Current Treatment Options in Infectious Diseases 7:4, pages 291-316.
Crossref
Crossref
N. T. Mutters, S. Zimmermann, M. Kaase & A. Mischnik. (2015) Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. European Journal of Clinical Microbiology & Infectious Diseases 34:12, pages 2429-2437.
Crossref
Crossref
Jose F. Camargo, Jacques Simkins, Thiago Beduschi, Akin Tekin, Laura Aragon, Armando Pérez-Cardona, Clara E. Prado, Michele I. Morris, Lilian M. Abbo & Rafael Cantón. (2015) Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy 59:10, pages 5903-5908.
Crossref
Crossref
Matteo Bassetti & Elda Righi. (2015) New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care 21:5, pages 402-411.
Crossref
Crossref
David P. Nicolau, Leonard Siew, Jon Armstrong, James Li, Timi Edeki, Maria Learoyd & Shampa Das. (2015) Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy 70:10, pages 2862-2869.
Crossref
Crossref
Hosam M. Zowawi, Patrick N. A. Harris, Matthew J. Roberts, Paul A. Tambyah, Mark A. Schembri, M. Diletta Pezzani, Deborah A. Williamson & David L. Paterson. (2015) The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology 12:10, pages 570-584.
Crossref
Crossref
Pierluigi Viale, Maddalena Giannella, Sara Tedeschi & Russell Lewis. (2015) Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Current Opinion in Pharmacology 24, pages 30-37.
Crossref
Crossref
Shampa Das, Jianguo Li, Jon Armstrong, Maria Learoyd & Timi Edeki. (2015) Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacology Research & Perspectives 3:5.
Crossref
Crossref
Keith S. Kaye & Jason M. Pogue. (2015) Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:10, pages 949-962.
Crossref
Crossref
Sergio E. Trevino, Hilary M. Babcock, Jeffrey P. Henderson, Michael A. Lane, Susan E. Beekmann, Philip M. Polgreen & Jonas Marschall. (2015) Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. Journal of Antimicrobial Chemotherapy, pages dkv271.
Crossref
Crossref
David M. Livermore, Marina Warner, Dorota Jamrozy, Shazad Mushtaq, Wright W. Nichols, Nazim Mustafa & Neil Woodford. (2015)
In Vitro
Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
. Antimicrobial Agents and Chemotherapy 59:9, pages 5324-5330.
Crossref
Crossref
Jordan L. Liscio, Monica V. Mahoney & Elizabeth B. Hirsch. (2015) Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents 46:3, pages 266-271.
Crossref
Crossref
Pierluigi Viale, Maddalena Giannella, Michele Bartoletti, Sara Tedeschi & Russell Lewis. (2015) Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. Infectious Diseases and Therapy 4:S1, pages 65-83.
Crossref
Crossref
Ronald N. Jones, Nicole M. Holliday & Kevin M. Krause. (2015) Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination. Antimicrobial Agents and Chemotherapy 59:8, pages 5036-5039.
Crossref
Crossref
Nobumitsu Tominaga, Timi Edeki, James Li, Maria Learoyd, M. René Bouw & Shampa Das. (2015) Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy 21:8, pages 551-558.
Crossref
Crossref
Evan J. Zasowski, Jeffrey M. Rybak & Michael J. Rybak. (2015) The β-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:8, pages 755-770.
Crossref
Crossref
Henrik Sillén, Richard Mitchell, Rebecca Sleigh, Guy Mainwaring, Katherine Catton, Richard Houghton & Karen Glendining. (2015) Determination of avibactam and ceftazidime in human plasma samples by LC–MS. Bioanalysis 7:12, pages 1423-1434.
Crossref
Crossref
Mamun-Ur Rashid, Staffan Rosenborg, Georgios Panagiotidis, Karin Söderberg Löfdal, Andrej Weintraub & Carl Erik Nord. (2015) Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. International Journal of Antimicrobial Agents 46:1, pages 60-65.
Crossref
Crossref
Alpesh N Amin & Dennis Deruelle. (2015) Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiology 10:6, pages 1049-1062.
Crossref
Crossref
Henri Merdjan, Manickam Rangaraju & Antoine Tarral. (2015) Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies. Clinical Drug Investigation 35:5, pages 307-317.
Crossref
Crossref
Haley J. Morrill, Jason M. Pogue, Keith S. Kaye & Kerry L. LaPlante. (2015) Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases 2:2.
Crossref
Crossref
Vincent Dubée, Audrey Bernut, Mélanie Cortes, Tiffany Lesne, Delphine Dorchene, Anne-Laure Lefebvre, Jean-Emmanuel Hugonnet, Laurent Gutmann, Jean-Luc Mainardi, Jean-Louis Herrmann, Jean-Louis Gaillard, Laurent Kremer & Michel Arthur. (2015)
β-Lactamase inhibition by avibactam in
Mycobacterium abscessus
. Journal of Antimicrobial Chemotherapy 70:4, pages 1051-1058.
Crossref
Crossref
Antoine Tarral & Henri Merdjan. (2015) Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers. Clinical Therapeutics 37:4, pages 877-886.
Crossref
Crossref
Matteo Bassetti & Elda Righi. (2015) Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbeck's Archives of Surgery 400:2, pages 153-165.
Crossref
Crossref
U-Im ChangHyung Wook KimYong-sun NohSeong-Heon Wie. (2015) A comparison of the clinical characteristics of elderly and non-elderly women with community-onset, non-obstructive acute pyelonephritis. The Korean Journal of Internal Medicine 30:3, pages 372.
Crossref
Crossref
U-Im ChangHyung Wook KimSeong-Heon Wie. (2015) Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis. Yonsei Medical Journal 56:5, pages 1266.
Crossref
Crossref
Kimberly A. Toussaint & Jason C. Gallagher. (2014) β-Lactam/β-Lactamase Inhibitor Combinations. Annals of Pharmacotherapy 49:1, pages 86-98.
Crossref
Crossref
Shachaf Shiber, Dafna Yahav, Tomer Avni, Leonard Leibovici & Mical Paul. (2015) β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 70:1, pages 41-47.
Crossref
Crossref
Gerard R. Barber & Amar Safdar. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
440
446.e2
.
William A. Craig & David R. Andes. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
278
292.e4
.
M. Bassetti, P. Della Siega & D. Pecori. 2015. Annual Update in Intensive Care and Emergency Medicine 2015. Annual Update in Intensive Care and Emergency Medicine 2015
63
83
.
Takanori Asakura, Masayuki Ikeda, Akira Nakamura & Satoshi Kodera. (2014) Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. International Journal of Infectious Diseases 29, pages 91-95.
Crossref
Crossref
Premavathy Levasseur, Anne-Marie Girard, Ludovic Lavallade, Christine Miossec, John Pace & Kenneth Coleman. (2014) Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases. Antimicrobial Agents and Chemotherapy 58:11, pages 6490-6495.
Crossref
Crossref
Shawn H. MacVane, Jared L. Crandon, Wright W. Nichols & David P. Nicolau. (2014)
In Vivo
Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates
. Antimicrobial Agents and Chemotherapy 58:11, pages 6913-6919.
Crossref
Crossref
Robert K. Flamm, Helio S. Sader, David J. Farrell & Ronald N. Jones. (2014) Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagnostic Microbiology and Infectious Disease 80:3, pages 233-238.
Crossref
Crossref
Sarah S. Tang, Anucha Apisarnthanarak & Li Yang Hsu. (2014) Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Advanced Drug Delivery Reviews 78, pages 3-13.
Crossref
Crossref
Garyphallia Poulakou, Matteo Bassetti, Elda Righi & George Dimopoulos. (2014) Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiology 9:9, pages 1053-1069.
Crossref
Crossref
Ken Coleman, Premavathy Levasseur, Anne-Marie Girard, Monica Borgonovi, Christine Miossec, Henri Merdjan, George Drusano, David Shlaes & Wright W. Nichols. (2014) Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy 58:6, pages 3366-3372.
Crossref
Crossref
R. K. Flamm, D. J. Farrell, H. S. Sader & R. N. Jones. (2014) Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). Journal of Antimicrobial Chemotherapy 69:6, pages 1589-1598.
Crossref
Crossref
M. J. Satlin, S. G. Jenkins & T. J. Walsh. (2014) The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies. Clinical Infectious Diseases 58:9, pages 1274-1283.
Crossref
Crossref
Sarah M. Drawz, Krisztina M. Papp-Wallace & Robert A. Bonomo. (2014) New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World. Antimicrobial Agents and Chemotherapy 58:4, pages 1835-1846.
Crossref
Crossref
Seth T. Housman, Jared L. Crandon, Wright W. Nichols & David P. Nicolau. (2014) Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy 58:3, pages 1365-1371.
Crossref
Crossref
Shampa Das, Jon Armstrong, David Mathews, Jianguo Li & Timi Edeki. (2014) Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. The Journal of Clinical Pharmacology 54:3, pages 331-340.
Crossref
Crossref
V. Cattoir. (2013) Infections à bacilles à Gram négatif résistants : nouvelles molécules, nouvelles associations. Journal des Anti-infectieux 15:4, pages 159-165.
Crossref
Crossref
Antonis Markogiannakis, Leonidas S Tzouvelekis, Mina Psichogiou, Efi Petinaki & George L Daikos. (2013)
Confronting carbapenemase-producing
Klebsiella pneumoniae
. Future Microbiology 8:9, pages 1147-1161.
Crossref
Crossref
Mercedes Delgado-Valverde, Jesús Sojo-Dorado, Álvaro Pascual & Jesús Rodríguez-Baño. (2013)
Clinical management of infections caused by multidrug-resistant
Enterobacteriaceae
. Therapeutic Advances in Infectious Disease 1:2, pages 49-69.
Crossref
Crossref
George G. Zhanel, Christopher D. Lawson, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Philippe R. S. Lagacé-Wiens, Andrew Denisuik, Ethan Rubinstein, Alfred S. Gin, Daryl J. Hoban, Joseph P. Lynch3rd3rd & James A. Karlowsky. (2013) Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination. Drugs 73:2, pages 159-177.
Crossref
Crossref